Detalles de la búsqueda
1.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068504
2.
A Phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors.
Future Oncol
; 17(21): 2747-2758, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-33849298
3.
Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies.
Br J Haematol
; 170(5): 669-78, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25942994
4.
A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors.
Invest New Drugs
; 32(5): 976-84, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24894650
5.
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Invest New Drugs
; 32(5): 937-45, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24916770
6.
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program.
Clin Pharmacol Ther
; 2024 Mar 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38519861
7.
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
; 29(19): 3882-3891, 2023 10 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37490286
8.
[Baseline drift of electrocardiograph dealt with mathematical morphology filter in real-time].
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
; 27(1): 48-52, 2010 Feb.
Artículo
en Zh
| MEDLINE | ID: mdl-20337023
9.
[Determination of the components of bitespiramycin by HPLC].
Yao Xue Xue Bao
; 44(10): 1183-6, 2009 Oct.
Artículo
en Zh
| MEDLINE | ID: mdl-20055146
10.
Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
Cancer Chemother Pharmacol
; 76(5): 1041-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26429709
11.
Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia.
Cancer Chemother Pharmacol
; 74(3): 593-602, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25053389
12.
Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
Anticancer Res
; 34(4): 2001-6, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24692738
Resultados
1 -
12
de 12
1
Próxima >
>>